Dynanonic(SZ:300769) Huachuang Securities·2025-09-12 13:08Investment Rating - The report maintains a "Strong Buy" rating for the company, expecting it to outperform the benchmark index by over 20% in the next six months [2][19]. Core Insights - The company's profits are under pressure due to price impacts, but high-end lithium iron phosphate (LiFePO4) research and development is progressing smoothly [2]. - The company reported a revenue of 3.882 billion yuan for H1 2025, a year-on-year decrease of 10.58%, with a net loss attributable to shareholders of 391 million yuan, an improvement from a loss of 516 million yuan in the same period last year [8]. - The company is increasing its R&D investment, with a total of 102 million yuan spent and 61 new patent applications filed during the reporting period [8]. Financial Performance Summary - Total revenue is projected to increase from 7.613 billion yuan in 2024 to 14.359 billion yuan in 2027, with a compound annual growth rate (CAGR) of 19.6% [4]. - The net profit attributable to shareholders is expected to improve from a loss of 1.338 billion yuan in 2024 to a profit of 434 million yuan in 2027, reflecting a significant turnaround [4]. - Earnings per share (EPS) is forecasted to rise from -4.77 yuan in 2024 to 1.55 yuan in 2027 [4]. Product Development and Market Position - The company has the largest established production capacity for manganese iron lithium at 110,000 tons per year, with products already in mass production [8]. - The first-generation manganese iron lithium product has achieved batch delivery, and the second-generation product is progressing well in validation [8]. - The company’s lithium supplement enhancer is the first in the world to achieve mass production, with a capacity of 5,000 tons per year, leading the industry in both scale and progress [8].